New hope for tough lymphoma: experimental drug GSK5926371 enters human trials

NCT ID NCT07607925

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also study how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK5926371
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma that has not responded to other therapies.
What could go wrong: This is an early-phase trial with only 49 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

GSK Investigational Site

Canton, Ohio, 44718, United States
GSK Investigational Site

Toronto, Ontario, M5G 1X6, Canada
GSK Investigational Site

Tokyo, 135-8550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.